How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/human-epidermal-growth-factor-2-positive-gastric-cancer.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Human epidermal growth factor 2 positive gastric cancer — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Human epidermal growth factor 2 positive gastric cancer (disease) competitive landscape: 5 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

5 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Human epidermal growth factor 2 positive gastric cancer, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Herceptin	Trastuzumab-Qyyp	Roche	HER2/neu receptor antagonist monoclonal antibody	HER2 (c-erbB2) proto-oncogene transmembrane receptor protein	1998-01-01
Herceptin	trastuzumab	Roche	Antibody-drug conjugate (ADC)	HER2 receptor, subdomain IV	1998-01-01
OGIVRI	TRASTUZUMAB-DKST	MYLAN GMBH	HER2/neu Receptor Antagonist [EPC]	Receptor tyrosine-protein kinase erbB-2
Herceptin	Herceptin	National Cancer Institute (NCI)		Receptor tyrosine-protein kinase erbB-2
Trastuzumab (Herceptin)	trastuzumab-herceptin	Pfizer Inc.		Receptor tyrosine-protein kinase erbB-2

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Roche · 2 drugs in Human epidermal growth factor 2 positive gastric cancer
MYLAN GMBH · 1 drug in Human epidermal growth factor 2 positive gastric cancer
National Cancer Institute (NCI) · 1 drug in Human epidermal growth factor 2 positive gastric cancer
Pfizer Inc. · 1 drug in Human epidermal growth factor 2 positive gastric cancer

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Human epidermal growth factor 2 positive gastric cancer:

Cite this brief

Drug Landscape (2026). Human epidermal growth factor 2 positive gastric cancer — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/human-epidermal-growth-factor-2-positive-gastric-cancer. Accessed 2026-06-10.

Human epidermal growth factor 2 positive gastric cancer full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing